ADVERTISEMENT
China’s Vaccine Front-Runner Aims to Beat Covid the Old-Fashioned Way
Sinovac Biotech relies on an inactive version of the novel coronavirus to teach human immune systems to destroy the real thing.
25 Aug 2020, 05:41 AM IST
(Bloomberg Businessweek) -- Many of the 200-plus Covid-19 vaccine projects under way around the world are focused on new technologies—inoculations based on messenger RNA, for example, or genetically modified cold viruses. The company developing one of China’s leading vaccine candidates, by contrast, is betting that humanity’s best chance may lie with a shot not too different from the kind that’s been in use for hundreds of years.
I’m already a Subscriber Sign In
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Lite
Experience
Members-Only
Rewards
NDTV Profit
Exclusive Stories
Full Access to
NDTV Profit App
Access to
Stories
20,000+
Research Reports
Ad-Lite
Experience
NDTV Profit
Exclusive Stories
Curated
Newsletters
Priority Pass
to Special Events
Members-Only
Rewards
Full Access to
NDTV Profit App
Still Not convinced ? Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
ADVERTISEMENT